32 completed, 11 terminated, 4 unknown, 3 active not recruiting. 29 Phase 2, 21 Phase 1, 7 Not applicable, 2 Phase 3.
Follow Stage IV Chronic Lymphocytic Leukemia: new trials by email Literature Review of Stage IV Chronic Lymphocytic Leukemia trials Research Report on Stage IV Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy Ibrutinib, Laboratory Biomarker Analysis - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 35 | 2016-02-08 | 2026-09-25 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Bendamustine Hydrochloride, Biospecimen Collection, Bone Marrow Aspiration - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 547 | 2014-01-15 | 2026-10-22 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Unknown | Chinese PLA General Hospital | 12 | 2013-04-01 | 2016-01-28 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant management of therapy complications, musculoskeletal complications management/prevention - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2012-05-01 | 2012-07-09 | |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study - Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Completed | OHSU Knight Cancer Institute | 19 | 2011-10-01 | 2021-04-08 |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia alemtuzumab, ofatumumab, biopsy - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Northwestern University | 53 | 2011-06-01 | 2025-05-23 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia Diagnostic Laboratory Biomarker Analysis, Lenalidomide - Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-12-01 | 2015-06-04 | |
| Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia laboratory biomarker analysis, western blotting, gene expression analysis - Refractory Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2010-12-01 | 2014-01-13 | |
| Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer palifermin, flow cytometry, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Not applicable | Completed | Martin, Paul | 6 | 2010-09-01 | 2014-04-02 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
Showing 20 of 53. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (53) · Lymphoma, Follicular (28) · Lymphoma, Large B-Cell, Diffuse (28) · Lymphoma, Mantle-Cell (28) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Lymphoma, B-Cell, Marginal Zone (22) · Burkitt Lymphoma (21) · Lymphoma, Non-Hodgkin (20) · Hodgkin Disease (19) · Leukemia, Prolymphocytic (19) · Lymphoma, Large-Cell, Immunoblastic (19) · Lymphoma, T-Cell, Cutaneous (19) · Leukemia, Myeloid, Accelerated Phase (18) · Mycosis Fungoides (18) · Sezary Syndrome (18)
Chronic Disease (53) · Disease Attributes (53) · Hematologic Diseases (53) · Hemic and Lymphatic Diseases (53) · Immune System Diseases (53) · Immunoproliferative Disorders (53) · Leukemia, B-Cell (53) · Leukemia, Lymphoid (53) · Lymphatic Diseases (53) · Lymphoproliferative Disorders (53) · Neoplasms (53) · Neoplasms by Histologic Type (53) · Pathologic Processes (53) · Pathological Conditions, Signs and Symptoms (53) · Leukemia (51)
Rituximab (11) · fludarabine phosphate (11) · Cyclophosphamide (10) · Mycophenolic Acid (6) · Tacrolimus (5) · Whole-Body Irradiation (5) · Cyclosporine (4) · Flow Cytometry (4) · Lenalidomide (4) · Peripheral Blood Stem Cell Transplantation (4) · Therapeutics (4) · alvocidib (4) · Alemtuzumab (3) · In Situ Hybridization, Fluorescence (3) · Antilymphocyte Serum (2)
National Cancer Institute (NCI) (18) · Fred Hutchinson Cancer Center (10) · Chinese PLA General Hospital (4) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · Amir Mortazavi (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · M.D. Anderson Cancer Center (1) · Martin, Paul (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1)
United States (46) · China (5) · Canada (2) · Italy (2) · Denmark (1) · Sweden (1)
Paul Martin (3) · Asher Chanan-Khan (2) · John Byrd (2) · Mazyar Shadman (2) · Ryotaro Nakamura (2) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1) · Asher Chanan-Khan, M.D. (1) · Brenda Cooper, MD (1) · David Maloney (1) · Francis Giles (1) · Janet Tooze, PhD (1) · Jennifer A Woyach (1) · Jennifer Brown (1)
PMID 32499241, PMID 34515338, PMID 18698002, PMID 23547837, PMID 23887852, PMID 24431228, PMID 25317870, PMID 25444722, PMID 26451310, PMID 26853648, PMID 26943915, PMID 27118540, PMID 27570087, PMID 28270022, PMID 28817727, PMID 29263894, PMID 29599530, PMID 30501481, PMID 30562587, PMID 31076448, PMID 31815579, PMID 32245502, PMID 32628342, PMID 33420905, PMID 33492438, PMID 34274940, PMID 36282798, PMID 38215395, PMID 40720747, PMID 41804087
P30CA015704 (5), U10CA031946 (4), U01CA076576 (3), P01CA018029 (2), P30CA016058 (2), U01CA062502 (2), U10CA180821 (2), K23CA178183 (1), N01CM62201 (1), N01CM62202 (1), P01CA078902 (1), P30CA014236 (1), P30CA014599 (1), P30CA015083 (1), P30CA016056 (1)